Announcements Trials
Browse Landscape

Phase

Phase NA 1

Status

Completed 3Unknown 1Terminated 1Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Thyroid Nodule 2Breast Neoplasms 2Thyroid Neoplasms 1Recurrence 1Pancreatic Neuroendocrine Tumors, WHO Grade I-II 1Neuroma 1Neuralgia 1Lymphoma, Follicular 1Liver Metastasis Colon Cancer 1Lipoma 1Klatskin Tumor 1Kidney Neoplasms 1Hypesthesia 1Esophageal Neoplasms 1Cicatrix 1Carcinoma, Hepatocellular 1Bone Cancer Metastatic 1Bile Duct Neoplasms 1Agnosia 1Adrenocortical Adenoma 1Adenoma, Islet Cell 1

Interventions

Cyclophosphamide 21venetoclax 18pembrolizumab 16Dexamethasone 16fludarabine 14Cytarabine 13Gemcitabine 9pomalidomide 8Rituximab 8Carboplatin 8Azacitidine 8glofitamab 7fludarabine phosphate 7Lenalidomide 7Immunotherapy, Adoptive 7selinexor 6Paclitaxel 6Injections 6Granulocyte Colony-Stimulating Factor 6Cisplatin 6daratumumab 5Temozolomide 5Oxaliplatin 5Bevacizumab 5zanubrutinib 4ruxolitinib 4Surgical Procedures, Operative 4Nivolumab 4Drug Therapy 4Decitabine 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Recruiting × Recurrence × Radiofrequency Ablation × Clear all
NCT03183115 2023-03-03

RFA to Prevent Metachronous Squamous Neoplasia Recurrence After Complete Endoscopic Submucosal Dissection

E-DA Hospital

Phase NA Recruiting
100 enrolled
Gastrointestinal

Esophageal Neoplasms, Recurrence

Data powered by HemOnc (CC BY 4.0) Colophon âš¡